Leyden Labs Raises €50M in European Funding Round

Why It Matters

The spray offers a novel, mucosal‑based prophylaxis that could dramatically improve respiratory‑virus protection, especially for high‑risk populations, and reshape flu prevention strategies worldwide.

Key Takeaways

• Intranasal spray targets virus at nasal entry point
• Science Translational Medicine study confirms safety and tolerance
• Efficacy surpasses traditional flu vaccines' average 13%
• €50 million European round fuels global expansion plans
• Platform may protect immunocompromised and elderly populations

Pulse Analysis

Traditional flu vaccines rely on systemic immunity, delivering antibodies through intramuscular injection. While effective at reducing severe disease, they often fall short in preventing infection, especially in older adults whose immune response wanes. Leyden Labs tackles this gap with a mucosal protection platform that administers engineered antibodies directly onto the nasal epithelium, the primary entry portal for respiratory viruses. By establishing a localized shield, the spray can neutralize pathogens before they replicate, offering a fundamentally different prophylactic strategy that aligns with emerging science on mucosal immunity.

The company's recent data, published in Science Translational Medicine, demonstrate that a single dose of the intranasal antibody formulation is safe, well‑tolerated, and maintains protective concentrations in the nasal lining for weeks. In head‑to‑head comparisons, the spray achieved infection‑prevention rates far above the 13 % average seen with conventional flu shots, and it showed cross‑reactivity against multiple influenza strains and several coronaviruses. Because the product works independently of the host’s adaptive response, it can complement existing vaccines, providing an extra layer of defense for high‑risk groups such as the elderly and immunocompromised.

Leyden Labs secured a €50 million funding round, underscoring investor confidence amid a challenging U.S. biotech financing environment. The capital will accelerate late‑stage clinical trials, expand manufacturing capacity, and support regulatory submissions across Europe and the United States. If approved, the spray could reshape the respiratory‑virus market, prompting insurers and public‑health agencies to consider non‑vaccine prophylaxis as part of seasonal flu strategies. The move also signals broader industry interest in antibody‑based, mucosal delivery systems that could address future pandemic threats.

Deal Summary

Leyden Labs, a biotech developing an intranasal antibody spray for flu protection, announced a recent €50 million European funding boost. The round will support further development and commercialization of its mucosal protection platform. The announcement was highlighted in a podcast interview with co‑founder Koenraad Wiedhaup and CSO Clarissa Koch.